TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24595633

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training and weight loss (AEX+WL)
Number of subjects: 16
Study: 24597398

Group type: EXPERIMENTAL
Intervention: Aortic stenosis (AS) valves
Number of subjects: 105

Group type: COMPARATOR
Intervention: Rheumatic aortic stenosis (RA) valves
Number of subjects: 105

Group type: COMPARATOR
Intervention: Endocarditis valves
Number of subjects: 105
Study: 24597865

Group type: EXPERIMENTAL
Intervention: ZFN-modified autologous CD4 T cells
Number of subjects: 12
Study: 24598035

Group type: EXPERIMENTAL
Intervention: Dietary intake and nutritional status assessment through various methods including dietary recall, food frequency questionnaire, and anthropometric measurements.
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Assessment of malaria parasitemia and intestinal helminth infestation.
Number of subjects: 551
Study: 24598452

Group type: EXPERIMENTAL
Intervention: 5 million EBV-CTLs/kg (1-3 doses)
Number of subjects: 11
Study: 24598881

Group type: EXPERIMENTAL
Intervention: Breast milk zinc concentration and total milk volume measured using deuterium oxide dose-to-mother tracer technique.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Breast milk zinc transfer measured using deuterium oxide dose-to-mother tracer technique.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Breast milk intake measured over time postpartum.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Birth weight and length measurements for AGA and SGA infants.
Number of subjects: 46
Study: 24599770

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 0
Study: 24600548

Group type: EXPERIMENTAL
Intervention: Epoprostenol (0.5 ng·kg(-1)·min(-1) for 72 hours, then tapered off over 24 hours)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 46
Study: 24602182

Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg IV every 3 weeks
Number of subjects: 30
Study: 24603020

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1851
Study: 24603117

Group type: EXPERIMENTAL
Intervention: 0.5 mg oral treprostinil TID for 7 days
Number of subjects: 19
Study: 24603195

Group type: EXPERIMENTAL
Intervention: Prelicence intervention (specific intervention details not provided)
Number of subjects: 7000
Study: 24603218

Group type: EXPERIMENTAL
Intervention: Gradient Gel Electrophoresis (GGE)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Vertical Auto Profile Ultracentrifugation (VAP-II)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Nuclear Magnetic Resonance Spectroscopy (NMR)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Ion Mobility
Number of subjects: 136
Study: 24604476

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily for 24 weeks
Number of subjects: 222
Study: 24604486

Group type: EXPERIMENTAL
Intervention: Pancreatic stone protein (PSP) and pancreatitis-associated protein (PAP) measured using a validated ELISA
Number of subjects: 160

Group type: COMPARATOR
Intervention: Regular inflammatory markers (c-reactive protein, procalcitonin, interleukin-6, tumour necrosis factor-α, leucocyte counts)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Total intensive care unit days and total length of stay
Number of subjects: 160
Study: 24606093

Group type: EXPERIMENTAL
Intervention: Metformin extended release 1500 mg/d for 12 weeks
Number of subjects: 36
Study: 24606096

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 12098

Group type: COMPARATOR
Intervention: No Growth Hormone (GH) treatment (Control)
Number of subjects: 12098
Study: 24606326

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab
Number of subjects: 30
Study: 24606567

Group type: EXPERIMENTAL
Intervention: 2 mg oral dose of trametinib
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 5 μg radiolabelled i.v. microdose of trametinib
Number of subjects: 4
Study: 24606768

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day plus trastuzumab (loading, 4 mg/kg; then weekly 2 mg/kg or loading, 8 mg/kg; then 3-weekly 6 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day plus trastuzumab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sunitinib plus trastuzumab
Number of subjects: 60
Study: 24606983

Group type: EXPERIMENTAL
Intervention: Thimerosal-containing QIV
Number of subjects: 56

Group type: COMPARATOR
Intervention: Thimerosal-containing TIV (historical control)
Number of subjects: 56
Study: 24607068

Group type: EXPERIMENTAL
Intervention: sifap1 study (5023 patients)
Number of subjects: 5023

Group type: COMPARATOR
Intervention: GQH registry (17007 patients)
Number of subjects: 5023

Group type: EXPERIMENTAL
Intervention: sifap1 study (4467 patients with ischaemic stroke or TIA)
Number of subjects: 5023

Group type: COMPARATOR
Intervention: GQH registry (14522 patients with ischaemic stroke or TIA)
Number of subjects: 5023

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 5023
Study: 24607242

Group type: EXPERIMENTAL
Intervention: Oral baclofen (titrated from 2.5 mg 3 times a day to a maximum of 20 mg 4 times a day)
Number of subjects: 49
Study: 24607558

Group type: EXPERIMENTAL
Intervention: Carbapenem exposure in AML patients
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Carbapenem exposure in aSCT recipients
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Previous exposure to carbapenems in both groups
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Incidence rates for CDI
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Median time from initiation of chemotherapy to CDI
Number of subjects: 375
Study: 24607560

Group type: EXPERIMENTAL
Intervention: HIV/STI services integrated with MCH care
Number of subjects: 8263

Group type: EXPERIMENTAL
Intervention: HIV counselling
Number of subjects: 8263

Group type: EXPERIMENTAL
Intervention: HIV/STI services with MCH care
Number of subjects: 8263

Group type: EXPERIMENTAL
Intervention: Integration of HIV services with ANC, CH, and FP
Number of subjects: 8263

Group type: EXPERIMENTAL
Intervention: HIV/Pnc integration
Number of subjects: 8263
Study: 24607562

Group type: EXPERIMENTAL
Intervention: Assessment of the impact of acute exacerbations of COPD (AECOPD) on health-related quality of life and healthcare resource utilization.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular diagnostic and typing techniques to describe the dynamics of airway infection during AECOPD and stable disease.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Refinement of the case definition of AECOPD to reflect possible microbiological aetiology.
Number of subjects: 0
Study: 24607563

Group type: EXPERIMENTAL
Intervention: Coronary catheterisation or PCI
Number of subjects: 11900
Study: 24607961

Group type: EXPERIMENTAL
Intervention: High-level recreational activity
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sedentary lifestyle
Number of subjects: 2
Study: 24609004

Group type: EXPERIMENTAL
Intervention: Structured patient education program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no structured patient education program)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison between groups at 3 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison between groups at 6 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline health related quality of life scores
Number of subjects: 50
Study: 24609720

Group type: EXPERIMENTAL
Intervention: High sensitivity IGF-1 measurement
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Refeeding index (RI)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Leptin alone
Number of subjects: 52
Study: 24610188

Group type: EXPERIMENTAL
Intervention: Gene Expression Score (GES) testing
Number of subjects: 251
Study: 24610431

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Medication (sertraline; SRT)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Combination of CBT and medication (COMB)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 488
Study: 24610872

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 312
Study: 24612927

Group type: EXPERIMENTAL
Intervention: Fosfomycin for patients with positive RUT
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Systematic use of RUT
Number of subjects: 347
Study: 24613652

Group type: EXPERIMENTAL
Intervention: Medical and Mental Health Unit
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care wards
Number of subjects: 60
Study: 24613995

Group type: EXPERIMENTAL
Intervention: Mexiletine administration to a carrier of the p.A997T-NaV1.5 mutation (1 individual)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: SCN5A mutations (13 of 584 patients, 2.2%)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Diarrhea-predominant IBS
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Constipation-predominant IBS
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Electrophysiologic analysis of NaV1.5 function
Number of subjects: 584

Group type: COMPARATOR
Intervention: Genome-wide association study
Number of subjects: 584
Study: 24614108

Group type: EXPERIMENTAL
Intervention: Gemcitabine infusion during PDAC resection
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Preoperative gemcitabine-based chemoradiotherapy
Number of subjects: 122
Study: 24614178

Group type: EXPERIMENTAL
Intervention: Sequential radioembolization-sorafenib therapy (sorafenib 400 mg twice-daily initiated 14 days post-radioembolization with yttrium-90 resin microspheres).
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sequential radioembolization-sorafenib therapy (sorafenib 600 mg median dose/day for a median duration of 4.1 months).
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sequential radioembolization-sorafenib therapy (with 90Y-microspheres).
Number of subjects: 29
Study: 24614383

Group type: EXPERIMENTAL
Intervention: Rifapentine (doses ranging from 450 to 1800 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifapentine (once-daily dosing over 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divided dosing of rifapentine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifapentine (compartmental model)
Number of subjects: 0
Study: 24614574

Group type: EXPERIMENTAL
Intervention: 8 RM loading (relative load)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 14 RM loading (relative load)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 20 RM loading (relative load)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 10% contraction failure
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 100% contraction failure
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Resting knee pain after final repetition
Number of subjects: 17
Study: 24614947

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m²) plus Cisplatin (25 mg/m²) on days 1 and 8, every 3 weeks for up to 24 weeks
Number of subjects: 18
Study: 24615776

Group type: EXPERIMENTAL
Intervention: Idelalisib (GS-1101, CAL-101) taken once or twice daily at doses ranging from 50 to 350 mg.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Idelalisib (GS-1101, CAL-101)
Number of subjects: 64
Study: 24615777

Group type: EXPERIMENTAL
Intervention: Idelalisib (GS-1101, CAL-101) at 6 dose levels (50-350 mg once or twice daily)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Idelalisib (GS-1101, CAL-101)
Number of subjects: 54
Study: 24615778

Group type: EXPERIMENTAL
Intervention: Idelalisib (50-350 mg daily or twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Idelalisib
Number of subjects: 40
Study: 24616160

Group type: EXPERIMENTAL
Intervention: RUNX1-RUNX1T1 DNA quantification using real-time quantitative PCR
Number of subjects: 22

Group type: COMPARATOR
Intervention: RUNX1-RUNX1T1 RNA detection
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MRD monitoring on genomic DNA
Number of subjects: 22
Study: 24616310

Group type: EXPERIMENTAL
Intervention: Mogamulizumab (1.0 mg/kg) administered intravenously once per week for 8 weeks
Number of subjects: 38
Study: 24617713

Group type: EXPERIMENTAL
Intervention: Vandetanib (tyrosine kinase inhibitor)
Number of subjects: 1
Study: 24618504

Group type: EXPERIMENTAL
Intervention: Magnetically guided capsule gastroscopy
Number of subjects: 189

Group type: COMPARATOR
Intervention: Conventional gastroscopy
Number of subjects: 189
Study: 24618589

Group type: EXPERIMENTAL
Intervention: GC1008 (fresolimumab) at doses of 0.1, 0.3, 1, 3, 10, or 15 mg/kg administered intravenously on days 0, 28, 42, and 56, followed by Extended Treatment of 4 doses every 2 weeks for up to 2 additional courses.
Number of subjects: 29
Study: 24619017

Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) using external beam three-dimensional conformal radiotherapy (3D-CRT) at a total dose of 36.9 Gy (nine fractions of 4.1 Gy b.i.d.)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) using external beam three-dimensional conformal radiotherapy (3D-CRT)
Number of subjects: 44
Study: 24619321

Group type: EXPERIMENTAL
Intervention: Combined arm (behavioral and medication management)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Behavioral arm
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Medication management arm
Number of subjects: 591

Group type: COMPARATOR
Intervention: Combined arm
Number of subjects: 591

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 591
Study: 24620740

Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fear for ECV and depression (measured by EDS scores)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obstetric factors (parity, placental location, BMI, engagement of fetal breech)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fear for ECV
Number of subjects: 0
Study: 24620844

Group type: EXPERIMENTAL
Intervention: Filtered P-SAECG signal
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Y lead
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Z lead
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Interatrial fat
Number of subjects: 90
Study: 24621049

Group type: EXPERIMENTAL
Intervention: Chronic spinal cord injury (SCI) participants
Number of subjects: 200
Study: 24621121

Group type: EXPERIMENTAL
Intervention: Pooled polymerase chain reaction (PCR) testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled PCR testing
Number of subjects: 0
Study: 24621973

Group type: EXPERIMENTAL
Intervention: Urinary tubular markers (NAG, KIM-1, NGAL)
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Urinary KIM-1
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF)
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Baseline glomerular filtration rate
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Urinary KIM-1, NAG, NGAL levels
Number of subjects: 2011
Study: 24622344

Group type: EXPERIMENTAL
Intervention: Pedometer + weekly prompts + SDT grounded texts
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pedometer + weekly prompts
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pedometer only
Number of subjects: 160

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 160
Study: 24622396

Group type: EXPERIMENTAL
Intervention: RSV MAARI
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Outpatient lower respiratory tract illness
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Emergency department visits
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Hospitalization (RSVH)
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Daycare attendance or nonmultiple-birth, preschool-aged siblings
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Chronologic age <3 months
Number of subjects: 1642
Study: 24622644

Group type: EXPERIMENTAL
Intervention: Budesonide applied in 8 logarithmically increasing concentrations (0-100 μg/ml) on subject's forearm.
Number of subjects: 27
Study: 24622709

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 24622806

Group type: EXPERIMENTAL
Intervention: Milk diet (semiskimmed milk-based diet, 1700 mg Ca/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cheese diet (semihard cow-cheese-based diet, 1700 mg Ca/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control diet (nondairy diet, ~500 mg Ca/d)
Number of subjects: 15
Study: 24623282

Group type: EXPERIMENTAL
Intervention: Vismodegib, 150 mg/d for a mean of 18.0 months (range, 11-24 months)
Number of subjects: 6
Study: 24623833

Group type: EXPERIMENTAL
Intervention: Maraviroc monotherapy for 10 days
Number of subjects: 40
Study: 24624090

Group type: EXPERIMENTAL
Intervention: Ephedrine (0.8-3.3 mg/min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion (0.02-0.07 mg/min)
Number of subjects: 24
Study: 24624891

Group type: EXPERIMENTAL
Intervention: AKDN classification
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: KDIGO classification
Number of subjects: 15773

Group type: COMPARATOR
Intervention: NKF's KDOQI classification
Number of subjects: 15773
Study: 24624930

Group type: EXPERIMENTAL
Intervention: Health education intervention (n=54)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention (n=54)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (n=49)
Number of subjects: 157
Study: 24624979

Group type: EXPERIMENTAL
Intervention: Disease-modifying therapy (DMT) compliance measured through pharmacy drug shipment records.
Number of subjects: 2966

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate and beta-interferons (half of the sample using each).
Number of subjects: 2966
Study: 24625556

Group type: EXPERIMENTAL
Intervention: Dose-dense chemoimmunotherapy with central nervous system prophylaxis
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: COMMD1 expression
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis of COMMD1 expression
Number of subjects: 51
Study: 24625687

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 44 mcg subcutaneously (IFN β-1a SC) three times weekly
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 23
Study: 24626872

Group type: EXPERIMENTAL
Intervention: Aztreonam for inhalation solution
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaire-Bronchiectasis (QOL-B) V3.0
Number of subjects: 89
Study: 24626885

Group type: EXPERIMENTAL
Intervention: Obese patients with mild OSA (n=39)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Obese patients with moderate to severe OSA (n=39)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-obese patients with mild OSA (n=66)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-obese patients with moderate OSA (n=66)
Number of subjects: 105
Study: 24626999

Group type: EXPERIMENTAL
Intervention: Multipoint pacing (MPP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional cardiac resynchronization therapy (CRT)
Number of subjects: 40
Study: 24627116

Group type: EXPERIMENTAL
Intervention: Transcranial B-mode ultrasound for volume estimation of hematoma
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Early hematoma expansion (EHE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Neurological deterioration
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Spot sign positive patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Spot sign negative patients
Number of subjects: 25
Study: 24627436

Group type: EXPERIMENTAL
Intervention: high-specific-activity carrier-free (123)I-iobenguane
Number of subjects: 12
Study: 24627529

Group type: EXPERIMENTAL
Intervention: NT-proBNP cut-off value of 600 pg·mL(-1)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: NT-proBNP ≥ 600 pg·mL(-1)
Number of subjects: 688
Study: 24628565

Group type: EXPERIMENTAL
Intervention: BD Drihep A-Line
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PICO50
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Portex Line Draw Plus
Number of subjects: 25
Study: 24628779

Group type: EXPERIMENTAL
Intervention: Anterograde peak diastolic flow velocities (pDV) in septal perforating branches
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: pDV ≥ 0.57 m/sec
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combined use of several parameters indicating collateral flow
Number of subjects: 108
Study: 24628963

Group type: EXPERIMENTAL
Intervention: XELBEVOCT regimen (octreotide LAR 20 mg monthly, metronomic capecitabine 2000 mg daily, intravenous bevacizumab 5 mg/kg every 2 weeks for 9 months)
Number of subjects: 45
Study: 24630140

Group type: EXPERIMENTAL
Intervention: 7-item abbreviated QLS
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: 4-item abbreviated QLS
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: Full QLS
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: 7-item and 4-item abbreviated QLS
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: Amotivation/apathy
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: Longitudinal change
Number of subjects: 1427
Study: 24630875

Group type: EXPERIMENTAL
Intervention: Catheter-based PFO closure
Number of subjects: 47

Group type: COMPARATOR
Intervention: PFO group
Number of subjects: 47
Study: 24631328

Group type: EXPERIMENTAL
Intervention: Sayana® Press (SP)
Number of subjects: 362
Study: 24631409

Group type: EXPERIMENTAL
Intervention: Cabozantinib (100mg or 40mg)
Number of subjects: 65